Selections of Genes and Methods of Using the Same for Diagnosis and for Targeting the Therapy of Select Cancers
Description of Invention:
Available for licensing and commercial development are selections of expressed genes that function to characterize neuroblastoma in patients, and methods of using the same for targeting the therapy of neuroblastoma and for predicting the outcome of the therapy. The invention also relates to the use of supervised pattern recognition methods, such as artificial neural networks using high dimensional data, such as gene expression profiling data, for the prognosis of patients with neuroblastoma to predict their outcome.
Currently, patients with neuroblastoma are classified into risk groups (e.g., according to the Children’s Oncology Group risk-stratification) to guide physicians in the choice of the most appropriate therapy. Despite this careful stratification, the survival rate for patients with high-risk neuroblastoma remains <30%, and it is not possible to predict which of these high-risk patients will survive or succumb to the disease. The inventors performed gene expression profiling using cDNA microarrays containing 42,578 clones and used artificial neural networks to develop an accurate predictor of survival for each individual patient with neuroblastoma. Using principal component analysis we found that neuroblastoma tumors exhibited inherent prognostic specific gene expression profiles, achieving 88% accuracy. They identified 19 genes, including 2 prognostic markers reported previously, MYCN and CD44, which correctly predicted outcome for 98% of these patients.
Inventors:
Javed Khan (NCI) Jun S. Wei (NCI) Braden T. Greer (NCI)
Patent Status:
DHHS Reference No. E-324-2001/2-US-01 -- U.S. Provisional Application No. 60/598,728 filed 03 Aug 2004
Relevant Publication:
Jun S. Wei, Braden T. Greer, Frank Westermann, Seth M. Steinberg, Chang-Gue Son, Qing-Rong Chen, Craig C. Whiteford, Sven Bilke, Alexei L. Krasnoselsky, Nicola Cenacchi, Daniel Catchpoole, Frank Berthold, Manfred Schwab, and Javed Khan, "Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Patients with Neuroblastoma", Cancer Research 64, 6883-6891, October 1, 2004.
Portfolios: Devices/Instrumentation Cancer
Cancer -Diagnostics-In Vitro-DNA Based Cancer -Diagnostics Cancer -Research Materials Devices/Instrumentation-Diagnostics Devices/Instrumentation-Software
For Additional Information Please Contact: Cristina Thalhammer-Reyero PhD MBA
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-4507
Email: thalhamc@mail.nih.gov
Fax: (301) 402-0220